ClinicalTrials.gg
CompletedNCT00731549ASPIREUpdated Nov 26, 2014Results posted

Intramuscular Depot Formulation of Aripiprazole as Maintenance Treatment in Patients With Schizophrenia

A Phase 3 interventional study of Aripiprazole IM Depot in Schizophrenia, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 214 sites in 28 countries. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2014-11-26.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,081
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 126 studies testing aripiprazole in Schizophrenia — 4 open to participants now, 4 under way, 1 of them phase 3. Aripiprazole · Schizophrenia.

Enrollment
3rd of 125
1,081 · median 130
Started
2008
with 7 others
Phase 3
34 of 126
1 open now
Registered
54th of 126
by date
Lead sponsor
44 of 126
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 126 studies testing aripiprazole in Schizophrenia, this one is the 3rd largest by enrollment of the 125 interventional ones that give a count, is one of 8 that started in 2008, is one of 34 in phase 3, and was the 54th registered.

Schizophrenia

3,574 studies on the registry are indexed under Schizophrenia; 496 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

4 of the 126 studies testing aripiprazole in Schizophrenia are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About aripiprazole

Aripiprazole: first FDA approval 2002 (ABILIFY), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 334 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 259 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 126 studies testing aripiprazole in Schizophrenia, or all of them as a file.
02

Study summary

To evaluate the overall effectiveness of aripiprazole intramuscular (IM) depot as maintenance treatment in patients with schizophrenia.

Read the detailed description

This will be an open-label, uncontrolled study which will enroll subjects from Phase 4 of Study 31-07-246 and Phase 3 of Study 31- 07-247 and new subjects not participating in Studies 246/247. The treatment history of subjects prior to enrollment in the open-label study will vary according to the design of the pivotal double-blind study (i.e., 31-07-246 or 31-07-247).

This open-label study will be comprised of phases similar to the pivotal double-blind studies (i.e., Studies 246/247): a screening phase (if applicable), a conversion phase (Phase 1, if applicable), an oral stabilization phase (Phase 2), and an IM depot open-label maintenance phase (Phase 3). Phase 3 will be a 52-week treatment period with a 26-week follow-up period.

During Phase 3 (the open-label maintenance phase) oral aripiprazole rescue medication will be allowed for subjects who do not meet stability criteria or meet the criteria for impending relapse/exacerbation of psychotic symptoms.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Aripiprazole
  • IM Depot
  • Schizophrenia
  • Intramuscular
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who are able to provide written and/or consent obtained from a legally acceptable representative (as require by IRB/IEC), prior to the initiation of any protocol-required procedures.
  • Male and female subjects 18 to 65 years of age, inclusive, at time of informed consent.
  • Subjects who complete Studies 246/247 or who withdrew from the double-blind maintenance phase of either study (Phase 4 of Study 246 or Phase 3 of Study 247), or new subjects not participating in Studies 246/247.
  • # Subjects who, in the investigator's judgment, require chronic treatment with an antipsychotic medication.
  • Subjects able to understand the nature of the study and follow protocol requirements, including the prescribed dosage regimens, tablet ingestion, IM depot injection, discontinuation of prohibited concomitant medications, who can read and understand the written word in order to complete patient-reported outcomes measures, and who can be reliably rated on assessment scales.

Exclusion criteria

Exclusion Criteria:

  • Subjects with a current diagnosis other than schizophrenia, including schizoaffective disorder, major depressive disorder, bipolar disorder, delirium, dementia, amnestic or other cognitive disorders. Also, subjects with borderline, paranoid, histrionic, schizotypal, schizoid or antisocial personality disorder.
  • Subjects with schizophrenia that are considered resistant/ to antipsychotic treatment by history or response only to clozapine.
  • Subjects with a significant risk of violent behavior or a significant risk of committing suicide based on history or investigator's judgment.
  • Subjects who currently meet DSM-IV-TR criteria for substance dependence; including alcohol and benzodiazepines, but excluding caffeine and nicotine, or two positive drug screens for cocaine.
  • Subjects who are known to be allergic, intolerant, or unresponsive to prior treatment with aripiprazole or other quinolinones.
  • Subjects with a history of to antipsychotic agents.
  • Subjects with a history of neuroleptic malignant syndrome or tardive dyskinesia at screening.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,081 participants (actual)

Study arms

  • Experimental
    1

    Active Treatment of aripiprazole IM depot (300mg or 400mg)

    Drug: Aripiprazole IM Depot

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Stable Participants at Baseline Who Remained Stable at Endpoint (Last Visit).

    "Stable" was defined as meeting all of the following criteria: Outpatient status; Positive and negative syndrome scale (PANSS) total score ≤ 80; Lack of specific psychotic symptoms on the PANSS as measured by a score of ≤ 4 on each of the following items (possible scores of 1 to 7 for each item): 1) conceptual disorganization 2) suspiciousness 3) hallucinatory behavior 4) unusual thought content; Clinical Global Impression of Severity (CGI-S) ≤ 4 (moderately ill); and Clinical Global Impression for Severity of Suicidality (CGI-SS) ≤ 2 (mildly suicidal) on Part 1 and ≤ 5 (minimally worsened) on Part 2. The percentage of stable participants at baseline who remain stable at endpoint (last visit) is described here.

    Time frame: Baseline to Week 52/Last visit

Secondary outcomes

  1. Percentage of Participants Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria.

    "Impending relapse criteria" was defined as meeting all the following criteria: 1) Clinical Global Impression of Improvement (CGI-I) ≥ 5 (minimally worse), AND an increase to score of \>4 and absolute increase of ≥ 2 on the individual PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content); or an increase to score \>4 and absolute increase of ≥ 4 on the combined 4 PANSS items on any of these PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content) OR 2) Hospitalization due to worsening of psychotic symptoms, but excluding hospitalization for psychosocial reasons, OR 3) CGI-SS score of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2, OR 4) Violent behavior resulting in clinically relevant self-injury, injury to another person, or property damage.

    Time frame: Weeks 2,4,8,12,16,20,24,28,32,36,40,44,48,52, and Last visit (upto 4 weeks ± 3 days after completion or withdrawal)

  2. Percentage of Participants Achieving Remission.

    Remission is defined as a score of ≤ 3 on each of the following specific PANSS items, maintained for a period of six months: delusions, unusual thought content, hallucinatory behavior, conceptual disorganization, mannerisms/posturing, blunted affect, social withdrawal, and lack of spontaneity.

    Time frame: Overall remission from Weeks 2,4,8,12,16,20,24,28,32,36,40,44,48 and 52

  3. Percentage of Participants Stable at Baseline and Remaining Stable at Week 28.

    "Stable" was defined as meeting all of the following criteria: Outpatient status; PANSS total score ≤ 80; Lack of specific psychotic symptoms on the PANSS as measured by a score of ≤ 4 on each of the following items (possible scores of 1 to 7 for each item): 1) conceptual disorganization 2) suspiciousness 3) hallucinatory behavior 4) unusual thought content; Clinical Global Impression of Severity (CGI-S) ≤ 4 (moderately ill); and Clinical Global Impression for Severity of Suicidality (CGI-SS) ≤ 2 (mildly suicidal) on Part 1 and ≤ 5 (minimally worsened) on Part 2. The percentage of stable participants at baseline who remain stable at Week 28 is described here.

    Time frame: Baseline to Week 28

  4. Percentage of Participants With Time to First Exacerbation of Psychotic Symptoms/Impending Relapse.

    Participants who first time meet relapse criteria were considered as having an event at date of exacerbation of psychotic symptoms/impending relapse. Time to first event was calculated as the earliest date of meeting one of relapse criteria. Limited concurrent treatment with oral aripiprazole was permitted as rescue therapy.

    Time frame: Baseline to Week 52

  5. Mean Change From Baseline to Endpoint (Last Visit) in Positive and Negative Syndrome Scale (PANSS) Total Score.

    PANSS total score (range 30-210) is the sum of the rating scores for 7 positive scale items, 7 negative scale items and 16 general psychopathology scale items from the PANSS scale. PANSS positive subscale score (range 7-49) is the sum of the rating scores for the 7 positive scale items from the PANSS scale. PANSS negative subscale score (range 7-49) is the sum of the rating scores for the 7 negative scale items from the PANSS scale. The severity of each scale is rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms.

    Time frame: Baseline, Weeks 12, 24, 52 and last visit

  6. Mean Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score.

    To assess CGI-S, the rater or physician will answer the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices include: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

    Time frame: Baseline, Weeks 12, 24, 52 and last visit

  7. Mean Change From Baseline to Endpoint in PANSS Positive and Negative Subscales.

    PANSS positive subscale score (range 7-49) is the sum of the rating scores for the 7 positive scale items from the PANSS scale. Positive subscale consists of 7 positive symptom constructs: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility). PANSS negative subscale score (range 7-49) is the sum of the rating scores for the 7 negative scale items from the PANSS scale. Negative subscale consists of 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive pathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking). The severity of each scale is rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms.

    Time frame: Baseline, Weeks 12, 24, 52 and last visit

  8. Mean Clinical Global Impression of Improvement (CGI-I) Score.

    To assess CGI-I the rater or physician will rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses will be compared to the participants condition at baseline. Response choices include: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.

    Time frame: Weeks 2, 4, 12, 24, 52 and last visit

  9. Percentage of Participants Who Discontinued Due to All Causes.

    Participants who discontinued due to any cause were noted. Limited concurrent treatment with oral aripiprazole was permitted as rescue therapy.

    Time frame: Baseline to Week 52

07

Results

Posted Nov 11, 2014

Participant flow

This open label Phase 3 study enrolled participants from the maintenance phase of study NCT00705783 (31-07-246) and study NCT00706654 (31-07-247) and new participants. Participants received aripiprazole intramuscular (IM) depot as maintenance treatment.

Participant flow — Overall Study
MilestoneAripiprazole 400/300 mg IM Depot
Started1081
Completed858
Not completed223
Withdrew: Lost to follow-up19
Withdrew: Met withdrawal criteria24
Withdrew: Physician decision16
Withdrew: Withdrawal by subject89
Withdrew: Protocol deviation1
Withdrew: Adverse event31
Withdrew: Lack of efficacy with ae37
Withdrew: Lack of efficacy without ae6

Outcome measures

PrimaryPercentage of Stable Participants at Baseline Who Remained Stable at Endpoint (Last Visit).

"Stable" was defined as meeting all of the following criteria: Outpatient status; Positive and negative syndrome scale (PANSS) total score ≤ 80; Lack of specific psychotic symptoms on the PANSS as measured by a score of ≤ 4 on each of the following items (possible scores of 1 to 7 for each item): 1) conceptual disorganization 2) suspiciousness 3) hallucinatory behavior 4) unusual thought content; Clinical Global Impression of Severity (CGI-S) ≤ 4 (moderately ill); and Clinical Global Impression for Severity of Suicidality (CGI-SS) ≤ 2 (mildly suicidal) on Part 1 and ≤ 5 (minimally worsened) on Part 2. The percentage of stable participants at baseline who remain stable at endpoint (last visit) is described here.

Time frame:
Baseline to Week 52/Last visit
Reported as:
Number · Percentage of participants
Percentage of Stable Participants at Baseline Who Remained Stable at Endpoint (Last Visit).
Percentage of participantsAripiprazole 400/300 mg IM Depot
Baseline (N=1075)100
Week 2 (N=1023)99.02
Week 4 (N=1045)99.14
Week 8 (N=1009)98.51
Week 12 (N=988)97.47
Week 16 (N=951)98.42
Week 20 (N=919)98.15
Week 24 (N=880)99.20
Week 28 (N=854)98.95
Week 32 (N=838)99.16
Week 36 (N=814)99.26
Week 40 (N=807)99.50
Week 44 (N=784)99.11
Week 48 (N=751)99.20
Week 52 (N=671)98.96
Last visit (N=1072)94.96
SecondaryPercentage of Participants Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria.

"Impending relapse criteria" was defined as meeting all the following criteria: 1) Clinical Global Impression of Improvement (CGI-I) ≥ 5 (minimally worse), AND an increase to score of \>4 and absolute increase of ≥ 2 on the individual PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content); or an increase to score \>4 and absolute increase of ≥ 4 on the combined 4 PANSS items on any of these PANSS items (conceptual disorganization, hallucinatory behavior, suspiciousness, unusual thought content) OR 2) Hospitalization due to worsening of psychotic symptoms, but excluding hospitalization for psychosocial reasons, OR 3) CGI-SS score of 4 (severely suicidal) or 5 (attempted suicide) on Part 1 and/or 6 (much worse) or 7 (very much worse) on Part 2, OR 4) Violent behavior resulting in clinically relevant self-injury, injury to another person, or property damage.

Time frame:
Weeks 2,4,8,12,16,20,24,28,32,36,40,44,48,52, and Last visit (upto 4 weeks ± 3 days after completion or withdrawal)
Reported as:
Number · Percentage of participants
Percentage of Participants Meeting Exacerbation of Psychotic Symptoms/Impending Relapse Criteria.
Percentage of participantsAripiprazole 400/300 mg IM Depot
Week 2 (N=1028)0.49
Week 4 (N=1049)0.48
Week 8 (N=1011)0.79
Week 12 (N=988)1.52
Week 16 (N=948)0.84
Week 20 (N=920)1.09
Week 24 (N=883)0.45
Week 28 (N=857)0.58
Week 32 (N=838)0.36
Week 36 (N=814)0.25
Week 40 (N=808)0.25
Week 44 (N=783)0.26
Week 48 (N=750)0.27
Week 52 (N=668)0.30
Last visit (N=1079)4.17
Overall (N=1079)8.25
SecondaryPercentage of Participants Achieving Remission.

Remission is defined as a score of ≤ 3 on each of the following specific PANSS items, maintained for a period of six months: delusions, unusual thought content, hallucinatory behavior, conceptual disorganization, mannerisms/posturing, blunted affect, social withdrawal, and lack of spontaneity.

Time frame:
Overall remission from Weeks 2,4,8,12,16,20,24,28,32,36,40,44,48 and 52
Reported as:
Number · Percentage of participants
Percentage of Participants Achieving Remission.
Percentage of participantsAripiprazole 400/300 mg IM Depot
Percentage of Participants Achieving Remission.51.7
SecondaryPercentage of Participants Stable at Baseline and Remaining Stable at Week 28.

"Stable" was defined as meeting all of the following criteria: Outpatient status; PANSS total score ≤ 80; Lack of specific psychotic symptoms on the PANSS as measured by a score of ≤ 4 on each of the following items (possible scores of 1 to 7 for each item): 1) conceptual disorganization 2) suspiciousness 3) hallucinatory behavior 4) unusual thought content; Clinical Global Impression of Severity (CGI-S) ≤ 4 (moderately ill); and Clinical Global Impression for Severity of Suicidality (CGI-SS) ≤ 2 (mildly suicidal) on Part 1 and ≤ 5 (minimally worsened) on Part 2. The percentage of stable participants at baseline who remain stable at Week 28 is described here.

Time frame:
Baseline to Week 28
Reported as:
Number · Percentage of participants
Percentage of Participants Stable at Baseline and Remaining Stable at Week 28.
Percentage of participantsAripiprazole 400/300 mg IM Depot
Baseline (N=1075)100
Week 28 (N=854)98.95
SecondaryPercentage of Participants With Time to First Exacerbation of Psychotic Symptoms/Impending Relapse.

Participants who first time meet relapse criteria were considered as having an event at date of exacerbation of psychotic symptoms/impending relapse. Time to first event was calculated as the earliest date of meeting one of relapse criteria. Limited concurrent treatment with oral aripiprazole was permitted as rescue therapy.

Time frame:
Baseline to Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants With Time to First Exacerbation of Psychotic Symptoms/Impending Relapse.
Percentage of participantsAripiprazole 400/300 mg IM Depot
Percentage of Participants With Time to First Exacerbation of Psychotic Symptoms/Impending Relapse.8.2
SecondaryMean Change From Baseline to Endpoint (Last Visit) in Positive and Negative Syndrome Scale (PANSS) Total Score.

PANSS total score (range 30-210) is the sum of the rating scores for 7 positive scale items, 7 negative scale items and 16 general psychopathology scale items from the PANSS scale. PANSS positive subscale score (range 7-49) is the sum of the rating scores for the 7 positive scale items from the PANSS scale. PANSS negative subscale score (range 7-49) is the sum of the rating scores for the 7 negative scale items from the PANSS scale. The severity of each scale is rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms.

Time frame:
Baseline, Weeks 12, 24, 52 and last visit
Reported as:
Mean · Units on a scale
Mean Change From Baseline to Endpoint (Last Visit) in Positive and Negative Syndrome Scale (PANSS) Total Score.
Units on a scaleAripiprazole 400/300 mg IM Depot
Week 12 (N=987)-1.69 ± 6.21
Week 24 (N=882)-2.55 ± 7.08
Week 52 (N=669)-3.55 ± 7.75
Last visit (N=1078)-1.72 ± 10.21
SecondaryMean Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score.

To assess CGI-S, the rater or physician will answer the following question: "Considering your total clinical experience with this particular population, how mentally ill is the participant at this time?" Response choices include: 0 = not assessed; 1 = normal, not ill at all; 2 = borderline mentally ill; 3 = mildly ill; 4 = moderately ill; 5 = markedly ill; 6 = severely ill; and 7 = among the most extremely ill participants.

Time frame:
Baseline, Weeks 12, 24, 52 and last visit
Reported as:
Mean · Units on a scale
Mean Change From Baseline in Clinical Global Impression of Severity (CGI-S) Score.
Units on a scaleAripiprazole 400/300 mg IM Depot
Week 12 (N=987)-0.11 ± 0.52
Week 24 (N=883)-0.17 ± 0.53
Week 52 (N=668)-0.24 ± 0.56
Last visit (N=1079)-0.14 ± 0.70
SecondaryMean Change From Baseline to Endpoint in PANSS Positive and Negative Subscales.

PANSS positive subscale score (range 7-49) is the sum of the rating scores for the 7 positive scale items from the PANSS scale. Positive subscale consists of 7 positive symptom constructs: delusions, conceptual disorganization, hallucinatory behavior, excitement, grandiosity, suspiciousness/persecution, and hostility). PANSS negative subscale score (range 7-49) is the sum of the rating scores for the 7 negative scale items from the PANSS scale. Negative subscale consists of 7 negative symptom constructs: blunted affect, emotional withdrawal, poor rapport, passive pathetic withdrawal, difficulty in abstract thinking, lack of spontaneity and flow of conversation, stereotyped thinking). The severity of each scale is rated on a 7-point scale, with a score of 1 indicating the absence of symptoms and a score of 7 indicating extremely severe symptoms.

Time frame:
Baseline, Weeks 12, 24, 52 and last visit
Reported as:
Mean · Units on a scale
Mean Change From Baseline to Endpoint in PANSS Positive and Negative Subscales.
Units on a scaleAripiprazole 400/300 mg IM Depot
Week 12 positive subscale score (N=987)-0.42 ± 2.11
Week 24 positive subscale score (N=882)-0.68 ± 2.26
Week 52 positive subscale score (N=669)-1.04 ± 2.53
Last visit positive subscale score (N=1078)-0.49 ± 3.38
Week 12 negative subscale score (N=987)-0.40 ± 2.40
Week 24 negative subscale score (N=882)-0.53 ± 2.52
Week 52 negative subscale score (N=669)-0.80 ± 2.94
Last visit negative subscale score (N=1078)-0.46 ± 3.19
SecondaryMean Clinical Global Impression of Improvement (CGI-I) Score.

To assess CGI-I the rater or physician will rate the participant's total improvement whether or not it is due entirely to drug treatment. All responses will be compared to the participants condition at baseline. Response choices include: 0 = not assessed, 1 = very much improved, 2 = much improved, 3 = minimally improved, 4 = no change, 5 = minimally worse, 6 = much worse, and 7 = very much worse.

Time frame:
Weeks 2, 4, 12, 24, 52 and last visit
Reported as:
Mean · Units on a scale
Mean Clinical Global Impression of Improvement (CGI-I) Score.
Units on a scaleAripiprazole 400/300 mg IM Depot
Baseline (N=1081)3.48 ± 0.82
Week 2 (N=1026)3.52 ± 0.85
Week 4 (N=1049)3.49 ± 0.86
Week 12 (N=987)3.42 ± 0.92
Week 24 (N=882)3.33 ± 0.98
Week 52 (N=669)3.25 ± 0.99
Last visit (N=1079)3.35 ± 1.10
SecondaryPercentage of Participants Who Discontinued Due to All Causes.

Participants who discontinued due to any cause were noted. Limited concurrent treatment with oral aripiprazole was permitted as rescue therapy.

Time frame:
Baseline to Week 52
Reported as:
Number · Percentage of participants
Percentage of Participants Who Discontinued Due to All Causes.
Percentage of participantsAripiprazole 400/300 mg IM Depot
Percentage of Participants Who Discontinued Due to All Causes.20.6

Adverse events

Collected over Phase 3 Week 1 to Week 52/Early termination.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aripiprazole 400/300 mg IM Depot—95/1,081 (8.8%)254/1,081 (23.5%)
Most frequent serious events
Showing 10 of 67
Most frequent serious events
EventAripiprazole 400/300 mg IM Depot
SchizophreniaPsychiatric disorders21/1081
Psychotic disorderPsychiatric disorders15/1081
Schizophrenia, paranoid typePsychiatric disorders5/1081
PneumoniaInfections and infestations4/1081
Suicide attemptPsychiatric disorders3/1081
Myocardial infarctionCardiac disorders2/1081
CholelithiasisHepatobiliary disorders2/1081
BronchitisInfections and infestations2/1081
CellulitisInfections and infestations2/1081
Intentional overdoseInjury, poisoning and procedural complications2/1081
Most frequent other events
Most frequent other events
EventAripiprazole 400/300 mg IM Depot
HeadacheNervous system disorders82/1081
NasopharyngitisInfections and infestations76/1081
AnxietyPsychiatric disorders73/1081
InsomniaPsychiatric disorders71/1081

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Aripiprazole 400/300 mg IM Depot
Mean41.2 ± 10.6
Sex: Female, Male
Sex: Female, Male(Participants)Aripiprazole 400/300 mg IM Depot
Female439
Male642
08

Study locations

214 sites
  • Chandler, Arizona 85226, United States
  • Anaheim, California 92804, United States
  • Cerritos, California 90703, United States
  • Chino, California 91710, United States
  • Escondido, California 92025, United States
  • Garden Grove, California 92845, United States
  • Glendale, California 91204, United States
  • Glendale, California 91206, United States
  • Imperial, California 92251, United States
  • La Habra, California 90631, United States
  • Los Angeles, California 90024, United States
  • National City, California 91950, United States
  • Oceanside, California 92056, United States
  • Orange, California 92868, United States
  • Pasadena, California 91106, United States
  • Pico Rivera, California 90660, United States
  • San Bernardino, California 92408, United States
  • San Diego, California 92102, United States
  • San Diego, California 92103, United States
  • Study Site
    San Diego, California 92123, United States
  • San Diego, California 92123, United States
  • Sherman Oaks, California 91403, United States
  • Torrance, California 90502, United States
  • Highlands Ranch, Colorado 80130, United States
  • Norwalk, Connecticut 06851, United States
  • Washington, District of Columbia 20016, United States
  • Bradenton, Florida 34208, United States
  • Coral Springs, Florida 33065, United States
  • Doral, Florida 33166, United States
  • Gainesville, Florida 32606, United States
  • Hollywood, Florida 33021, United States
  • Kissimmee, Florida 34741, United States
  • Maitland, Florida 32751, United States
  • Miami, Florida 33135, United States
  • Orange City, Florida 32763, United States
  • Orlando, Florida 32839, United States
  • Plantation, Florida 33317, United States
  • Tampa, Florida 33613, United States
  • Atlanta, Georgia 30328, United States
  • Chicago, Illinois 60612, United States
  • Chicago, Illinois 60640, United States
  • Hoffman Estates, Illinois 60169, United States
  • Oak Brook, Illinois 60523, United States
  • Indianapolis, Indiana 46222, United States
  • Baton Rouge, Louisiana 70808, United States
  • Baton Rouge, Louisiana 70809, United States
  • Lake Charles, Louisiana 70629, United States
  • New Orleans, Louisiana 70115, United States
  • Shreveport, Louisiana 71101, United States
  • Columbia, Maryland 21045, United States
  • Flowood, Mississippi 39232, United States
  • Kansas City, Missouri 64108, United States
  • St. Louis, Missouri 63109, United States
  • St. Louis, Missouri 63118, United States
  • North Platte, Nebraska 69101, United States
  • Albuquerque, New Mexico 87131, United States
  • Buffalo, New York 14213, United States
  • Buffalo, New York 14215, United States
  • Cedarhurst, New York 11516, United States
  • Holliswood, New York 11423, United States
  • Jamaica, New York 11418, United States
  • New York, New York 10003, United States
  • New York, New York 10027, United States
  • Rochester, New York 14615, United States
  • Hickory, North Carolina 28601, United States
  • Winston-Salem, North Carolina 27104, United States
  • Canton, Ohio 44718, United States
  • Cincinnati, Ohio 45219, United States
  • Cleveland, Ohio 44109, United States
  • Garfield Heights, Ohio 44125, United States
  • Middleburg Heights, Ohio 44130, United States
  • Toledo, Ohio 43609, United States
  • Oklahoma City, Oklahoma 73103, United States
  • Oklahoma City, Oklahoma 73112, United States
  • Oklahoma City, Oklahoma 73139, United States
  • Allentown, Pennsylvania 18104, United States
  • Jenkintown, Pennsylvania 19046, United States
  • Media, Pennsylvania 19063, United States
  • Philadelphia, Pennsylvania 19131, United States
  • Philadelphia, Pennsylvania 19139, United States
  • Pittsburgh, Pennsylvania 15213, United States
  • Sellersville, Pennsylvania 18960, United States
  • Charleston, South Carolina 29401, United States
  • Charleston, South Carolina 29407, United States
  • Charleston, South Carolina 29425, United States
  • Johnson City, Tennessee 37614-1707, United States
  • Memphis, Tennessee 38119, United States
  • Nashville, Tennessee 37212, United States
  • Austin, Texas 78731, United States
  • Austin, Texas 78754, United States
  • DeSoto, Texas 75115, United States
  • Richmond, Virginia 23230, United States
  • Bellevue, Washington 98007, United States
  • Bothell, Washington 98011, United States
  • Spokane, Washington 99204, United States
  • Milwaukee, Wisconsin 53226, United States
  • Buenos Aires, C1058AAJ, Argentina
  • Buenos Aires, C1405BOA, Argentina
  • Buenos Aires, C1425AHQ, Argentina
  • Cordoba, Cordoba, X5009BIN, Argentina

Showing the first 100 of 214 sites across 28 countries. Choose a country and city above to see the rest.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2008, a primary completion of Nov 2013 and a completion of Nov 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2014, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 5, 2008
First posted
Aug 11, 2008
Start
Dec 2008
Primary completionActual
Nov 2013
CompletionActual
Nov 2013
Results first posted
Nov 11, 2014
Last update
Nov 26, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 26, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00731549
Collaborators
Covance
Responsible party
Sponsor
First posted
Aug 11, 2008
Start date
Dec 2008
Primary completion
Nov 2013
Completion
Nov 2013
Results posted
Nov 11, 2014
Last update
Nov 26, 2014

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aripiprazole

Start the discussion